OncoGenex to begin Spruce clinical trial to evaluate lung cancer agent
The randomized, Phase 2 study sponsored by SCRI will evaluate if the addition of OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes. The study